

Application No. 10/734,149
Response dated October 24, 2005
Response to Action of October 12, 2005

- 2 -

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims

Claims 1 to 9 (canceled)

10. (previously presented) The method of claim 16, wherein the polypeptide and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide.

11. (previously presented) The method of claim 33, wherein the polypeptide and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide.

12. (currently amended) The method of claim 72 ~~[[34]]~~, wherein the polypeptide or ~~variant thereof~~ and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide or ~~variant thereof~~.

13. (currently amended) The method of claim 75 ~~[[35]]~~, wherein the polypeptide or variant thereof and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide or variant thereof.

14. (canceled)

15. (canceled)

16. (currently amended) A method of vaccinating a patient comprising administering an antigen other than CD14 and a polypeptide to the patient, wherein the polypeptide

Application No. 10/734,149
Response dated October 24, 2005
Response to Action of October 12, 2005

- 3 -

activates B cells, and is encoded by a nucleotide sequence that has at least 62.6% identity with the full length of SEQ ID NO:1 and that hybridizes thereto under high stringency conditions which include a wash step in 0.1xSSC, 1% SDS at 65°C for 3 hours.

Claims 17 to 32 (canceled)

33. (previously presented) The method of claim 16, wherein said identity is at least 74.2% identity.

Claims 34 to 37 (canceled)

38. (currently amended) The method of claim 16 ~~[[36]]~~, wherein the polypeptide includes the amino acid sequence identified as SEQ ID NO:4, ~~SEQ ID NO:5, or SEQ ID NO:6~~, or a conservatively substituted variant thereof which activate B cells.

39. (currently amended) The method of claim 33 ~~[[37]]~~, wherein the polypeptide includes the amino acid sequence identified as SEQ ID NO:4, ~~SEQ ID NO:5, or SEQ ID NO:6~~, or a conservatively substituted variant thereof which activate B cells.

40. (previously presented) The method of claim 16, wherein the polypeptide comprises the amino acid sequence identified as SEQ ID NO:4.

41. (canceled)

42. (canceled)

43. (previously presented) The method of claim 16, wherein the antigen and the polypeptide are conjugated to each other.

44. (previously presented) The method of claim 33, wherein the antigen and the polypeptide are conjugated to each other.

Application No. 10/734,149
Response dated October 24, 2005
Response to Action of October 12, 2005

- 4 -

45. (currently amended) The method of claim 13 [[34]], wherein the antigen and the polypeptide are conjugated to each other.

Claims 46 to 48 (canceled)

49. (currently amended) The method of claim 38, wherein the antigen and the polypeptide or variant thereof are conjugated to each other.

50. (currently amended) The method of claim 39, wherein the antigen and the polypeptide or variant thereof are conjugated to each other.

51. (previously presented) The method of claim 40, wherein the antigen and the polypeptide are conjugated to each other.

52. (canceled)

53. (canceled)

54. (currently amended) The method of claim 16, further comprising the step of mixing the antigen and said polypeptide ~~vaccine~~ prior to the administering step.

55. (previously presented) The method of claim 16, wherein the polypeptide is recombinant.

56. (previously presented) The method of claim 16 wherein the administering step includes administering the polypeptide in combination with a pharmaceutical excipient.

57. (canceled)

58. (previously presented) The method of claim 38, wherein the polypeptide or variant thereof and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide or variant thereof.

Application No. 10/734,149
Response dated October 24, 2005
Response to Action of October 12, 2005

- 5 -

59. (previously presented) The method of claim 39, wherein the polypeptide or variant thereof and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide or variant thereof.

60. (previously presented) The method of claim 40, wherein the polypeptide and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide.

61. (canceled)

62. (canceled)

63. (new) The method of claim 10, further comprising the step of mixing the antigen and said polypeptide prior to the administering step.

64. (new) The method of claim 11, further comprising the step of mixing the antigen and said polypeptide prior to the administering step.

65. (new) The method of claim 13, further comprising the step of mixing the antigen and said polypeptide prior to the administering step.

66. (new) The method of claim 33, further comprising the step of mixing the antigen and said polypeptide prior to the administering step.

67. (new) The method of claim 40, further comprising the step of mixing the antigen and said polypeptide prior to the administering step.

68. (new) The method of claim 40, wherein the polypeptide is recombinant.

69. (new) The method of claim 10 wherein the administering step includes administering the polypeptide in combination with a pharmaceutical excipient.

Application No. 10/734,149
Response dated October 24, 2005
Response to Action of October 12, 2005

- 6 -

70. (new) The method of claim 33 wherein the administering step includes administering the polypeptide in combination with a pharmaceutical excipient.

71. (new) The method of claim 40 wherein the administering step includes administering the polypeptide in combination with a pharmaceutical excipient.

72. (new) The method of claim 51 wherein the administering step includes administering the polypeptide in combination with a pharmaceutical excipient.

73. (new) The method of claim 54 wherein the administering step includes administering the polypeptide in combination with a pharmaceutical excipient.

74. (new) The method of claim 67 wherein the administering step includes administering the polypeptide in combination with a pharmaceutical excipient.

75. (new) The method of claim 70, wherein the polypeptide is recombinant.